...metabolic orphan drug company Azafaros B.V., GPCR therapeutics company Confo Therapeutics N.V. and NASH play NorthSea Therapeutics B.V....

...fatty acid platform and a candidate that can hit the three primary mechanisms behind NASH, NorthSea...
...can succeed in the hepatic and cardiometabolic disease space where so many others have failed. NorthSea Therapeutics B.V....
...SEFAs were in-licensed from Pronova BioPharma Norge A/S, a subsidiary of BASF AG (Xetra:BAS), when NorthSea...

...to pursue another opportunity. Spero has begun a search for a successor. Non-alcoholic steatohepatitis company NorthSea Therapeutics B.V....
...at Epizyme Inc. (NASDAQ:EPZM). BC Staff AbCellera Biologics Inc. Aristea Therapeutics Inc. Cabaletta Bio Inc. Fulcrum Therapeutics Inc. Locate Bio Ltd. Modag GmbH NorthSea Therapeutics B.V. Spero...

...fund co-founded nearly a third of its 14 portfolio companies, including non-alcoholic steatohepatitis (NASH) company Northsea Therapeutics B.V....

...12, former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V....
...by Forbion and BioGeneration Ventures (BGV), with participation by Novo Seeds and New Science Ventures. NorthSea...
...worldwide rights to icosabutate. Terms of the deal were not disclosed. NorthSea Therapeutics B.V., Naarden, the Netherlands Chris Lieu PRC-4016 icosabutate NorthSea PRB-1022...

...Former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden...
...by Forbion and BioGeneration Ventures (BGV), with participation by Novo Seeds and New Science Ventures. NorthSea...
...NASDAQ:AMGN) in 2015 for $300 million up front and up to $1.3 billion in milestones. NorthSea...